US health reform bill will hinder introduction of generic forms of biological drugs, critics say

BMJ 2009; 339 doi: 10.1136/bmj.b4088 (Published 6 October 2009)
Cite this as: BMJ 2009;339:b4088

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. 1New York

    Medical students and consumer groups in the United States have objected to parts of the proposed healthcare reform bills, which they say will make it more difficult to introduce cheap generic forms of biological drugs (drugs derived biologically rather than chemically).

    The American Medical Students Association and the consumer groups Universities Allied for Essential Medicines, Essential Action, and Knowledge Ecology International say that provisions in several Senate and House of Representatives healthcare reform bills will block the introduction of most generic biologicals. Improving the proposed bills could save $71bn (£45bn; €49bn) …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL